Evidence map›Paper›PMID 42477366›Full record

ArticleNature communications2026

Accurate, sensitive, and efficient chromatin accessibility quantification at target loci using UNIChro-seq.

Michihiro Kono, Hiroaki Hatano, Kenichiro Asahara, Masahiro Nakano, Reza Bagherzadeh, Tsugumi Kawashima, Takahiro Arakawa, Miho Sato, Hajime Inokuchi, Takahiro Nishino and 6 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Michihiro Kono *Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan.ORCID http://orcid.org/0000-0003-2245-943X
Hiroaki Hatano *Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan.
Kenichiro AsaharaLaboratory for Human Immunogenetics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
Masahiro NakanoLaboratory for Human Immunogenetics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
Reza BagherzadehDepartment of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan.
Tsugumi KawashimaLaboratory for Human Immunogenetics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
Takahiro ArakawaLaboratory for Human Immunogenetics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.ORCID http://orcid.org/0000-0002-7061-5196
Miho SatoLaboratory for Human Immunogenetics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
Hajime InokuchiDepartment of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan.
Takahiro NishinoDepartment of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan.
Takahiro ItamiyaLaboratory for Human Immunogenetics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.ORCID http://orcid.org/0000-0002-1020-0108
Haruka TakahashiDepartment of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan.
Bunki NatsumotoLaboratory for Human Immunogenetics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
Akari SuzukiLaboratory for Autoimmune Diseases, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
Kazuhiko YamamotoLaboratory for Autoimmune Diseases, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
Kazuyoshi IshigakiDepartment of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan. kazuyoshi.ishigaki@keio.jp.ORCID http://orcid.org/0000-0003-2881-0657

Funding

Daiichi Sankyo Foundation of Life Science NAJapan Agency for Medical Research and Development (AMED) JP22tm0424223, JP22ek0410099, JP23tm0524005, JP25ek0410139, JP22ama121015 and JP223fa627010MEXT | Japan Society for the Promotion of Science (JSPS) 22H03114, 21K20647Mochida Memorial Foundation for Medical and Pharmaceutical Research NAUehara Memorial Foundation NA
6 · The paper itself

Abstract

Recent progress in statistical and experimental fine mapping of disease risk variants prompts us to focus on specific target loci for functional investigation. However, current genetics is hindered by a limited toolbox for target-loci analysis. To address this, we present UNIChro-seq, a method that digitally counts accessible chromatin molecules at target loci. UNIChro-seq allows for accurate, sensitive, and efficient quantification of allelic effects compared to conventional methods. Using UNIChro-seq, we investigate the effects of 57 autoimmunity risk alleles on chromatin accessibility and estimate the causal effects of 20 artificial variants generated through genome editing. As a caveat, a non-negligible fraction of the edited alleles exhibits a falsely positive effect on chromatin accessibility, which can be effectively distinguished from the true causal effect through bi-directional genome editing. Finally, functional dissection of a fine-mapped risk variant at the LEF1 locus illuminates its relevance to T cell dysregulation in rheumatoid arthritis. Together, these findings underscore the utility of combining UNIChro-seq with genome editing technology to enable precise and scalable functional analysis of disease-associated loci.

Indexed as

ChromatinAllelesAnimalsArthritis, RheumatoidGene EditingGenetic LociHigh-Throughput Nucleotide SequencingHumansLymphoid Enhancer-Binding Factor 1Sequence Analysis, DNAT-LymphocytesChromatinLymphoid Enhancer-Binding Factor 1

Identifiers

PMID42477366
PMCPMC13493992

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.